We support leading research projects in key research institutes and organisations across Australia.
Two projects from the Children's Cancer Institute were considered to be outstanding by the Neuroblastoma Australia Scientific Advisory Board and have been recommended for grants of $125,000 each for 2020.
We currently support the following research projects at the CCI:
CBL137 single agent clinical trials
CBL137 in combination with other targeted therapies
Characterisation of high-risk neuroblastoma models to support translational research
Optimisation of high-risk neuroblastoma model development
Improved preclinical efficacy of CBL0137 by combination with HDAC inhibition
Improving the long-term health of Australian childhood cancer survivors. While it is critical we continue to support research projects designed to improve the survival rates of children diagnosed with neuroblastoma, many children who do survive face ongoing physical and emotional health complications. These are often referred to as ‘late effects’.
The development of new and more effective therapies is key to improving the outcomes for children with this devastating disease. The Peter MacCallum Cancer Centre has pioneered the use of peptide receptor radionuclide therapy (PRRT) in neuroblastoma as an alternative therapy, especially in cases that have failed conventional treatment approaches.